MORPHOLOGY AND CELL IMAGING CORE
形态学和细胞成像核心
基本信息
- 批准号:7767528
- 负责人:
- 金额:$ 12.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-12-01 至 2014-11-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAntibodiesArtsBiosensorCalciumCell physiologyCellsCellular biologyChargeCollaborationsCommunitiesComputer softwareDiseaseEffectivenessElectrophysiology (science)EnsureEquipmentFunctional ImagingFundingGoalsHormonalHousingHuman ResourcesImageImage AnalysisImaging TechniquesImaging technologyInstitutesInvestigationLabelLaboratoriesLasersLeadershipLifeMaintenanceMedicineMethodologyMicroscopeMonoclonal AntibodiesMorphologyMusNanotechnologyNeurobiologyNeuronsPathogenesisPathologistPathologyPathway interactionsPlayProteinsPublicationsQuantum DotsReagentResearchResearch InstituteResearch PersonnelResearch Project GrantsResource SharingResourcesRoleSecond Messenger SystemsServicesSignal PathwaySignal TransductionSignaling MoleculeSystemTechnical ExpertiseTechnologyTissuesTrainingUpdatebrain researchcell typecellular imagingexperiencegastrointestinalimprovedinstrumentationinterestmacromoleculemedical schoolsmemberpatch clampprogramsreceptorresponsesecond messenger
项目摘要
The Morphology and Cell Imaging Core has been providing expertise, technical support and
assistance for morphological and imaging approaches as well as state-of-the-art equipment for
sophisticated imaging techniques to the DDRCC members for over 18 years under the leadership of Dr.
Sternini. The services provided by the core have been instrumental for studies that have elucidated the
tissue and cellular distribution of signaling molecules that play a role in the control of gastrointestinal
(Gl) function and in the pathogenesis of Gl disorders as well as for visualizing signaling pathways that
regulate cellular functions. The studies that have benefited from the core have made important
advances in our understanding of functional interactions between neuronal and hormonal pathways
regulating Gl functions and have resulted in many publications and in long-lasting collaborations.
There have been several additions and updates in services throughout the years to reflect the needs
of DDRCC members and the evolving of morphological and imaging technologies, with the goal of
enhancing the Core capabilities. Enhancement of morphological capabilities includes 1) the
addition of mouse pathology services and 2) the incorporation of a Central Bank of well
characterized antibodies. The mouse pathology services have been added in our previous competitive
renewal in response to the increasing need of many CURE: DDRCC investigators for expertise and
assistance in defining phenotypical abnormalities or pathologies that can be detected in genetically
manipulated mice, which are increasingly used at CURE:DDRCC. Dr. Nora Rozengurt, an experienced
veterinary pathologist with extensive expertise in natural and experimentally induced mouse pathology
has been serving as Core Associate Director to supervise this service, which has been extensively used
during the past funded cycle. The antibodies central bank has been added to provide a centralized
system for the wealth of antibodies that have been produced at CURE during previous funding periods
and for other antibodies that are used by many investigators as markers for specific cell types or
intracellular signaling molecules. The availability of a centralized bank of well characterized and
validated antibodies of interest to CURE: DDRCC investigators is a powerful resource that will allow an
effective access of CURE:DDRCC investigators to a variety of reagents that can be utilized through the
Morphology and Cell Imaging Core. Dr. Gordon Ohning will join the Core as Associate Director to be in
charge of the maintenance of the Central Bank of antibodies.
There has been a significant enhancement of the capabilities of our imaging services, including 1)
the addition of highly sophisticated equipment and 2) the incorporation of new imaging technologies that
will further advance our ability to visualize molecules at the cellular and subcellular levels and changes
in second messenger systems following cellular activation. A major enrichment of our imaging
facilities has been the addition of a state-of-the-art confocal microscope, a Zeiss LSM 510 Meta
equipped with sophisticated software (e.g. deconvolution, image analysis, 3-D rendering) for
live and fixed cell imaging. This system was acquired with the help of institutional funds from the
David Geffen UCLA School of Medicine just prior to the previous competitive renewal, and since then it
has been used heavily by an increasing number of CURE: DDRCC investigators. During the past
funded cycle, we have also enhanced our instrumentation for calcium imaging by acquiring a Zeiss
Pascal confocal microscope equipped with both short (405 nm) and visible wavelength lasers for
excitation. A whole cell patch clamp recording setup is available to perform single cell
electrophysiology simultaneously with confocal live cell imaging. This microscope, which has also
been acquired with the help of institutional funds from the School of Medicine Dean's office, is housed at
UCLA in the same building as the Zeiss 510 Meta confocal and has been extensively used by severa
DDRCC investigators. Our services have also been upgraded by the addition of new imaging
technologies in live cells, including quantum dots (Q-dots), photoactivatable proteins and
second messengers' biosensors labeled with fluorescent tags. These significant improvements will
further advance our ability to visualize macromolecules at the cellular and subcellular levels and
changes in second messenger systems following cellular activation. Dr. Osvaldo Rey will join the Core
personnel as Core Co-Director to supervise the new imaging methodologies that are proposed to cover
the new needs of many DDRCC investigators.
Finally, there will be an increased use of shared resources that are available for CURE: DDRCC
investigators through arrangements made by the Core Director and existing Cores at UCLA, which are
supported by the Department of Pathology and Laboratory Medicine, the Brain Research Institute and
the Nanotechnology Institute. These interactions will continue to be a major effort of the Morphology and
Cell Imaging Core to enhance the technical capabilities of the Core and ensure optimal utilization of
shared resources within the UCLA community that includes the CURE: DDRCC community.
Overall, the addition of services briefly outlined above and explained in more detail later in the body
of the application reflects the evolving of the DDRCC research interests and focus, and the advances in
morphological and imaging technologies. These additions will provide state-of-the-art approaches and
equipment to many CURE: DDRCC investigators who are interested in elucidating fundamental normal
or abnormal mechanisms in different types of cells controlling digestive functions.
形态学和细胞成像核心一直在提供专业知识,技术支持,
协助形态学和成像方法以及最先进的设备,
先进的成像技术,以DDRCC成员超过18年的领导下,博士。
斯特尼尼核心小组提供的服务有助于开展研究,阐明
组织和细胞分布的信号分子,发挥作用,在控制胃肠道
(Gl)功能和在GI疾病的发病机制中的作用,以及用于可视化信号通路,
调节细胞功能。从核心中受益的研究已经使重要的
我们对神经元和激素通路之间的功能相互作用的理解的进展
调节GI功能,并导致许多出版物和长期合作。
这些年来,为了反映需求,
以及形态学和成像技术的发展,其目标是
增强核心能力。形态学能力的增强包括:1)
增加小鼠病理学服务和2)成立中央银行,
特征抗体。小鼠病理学服务已被添加到我们以前的竞争
更新,以满足许多CURE:DDRCC研究人员对专业知识和
帮助定义可以在遗传学上检测到的表型异常或病理,
操纵的小鼠,这是越来越多地使用在治愈:DDRCC。诺拉·罗森古特医生,一位经验丰富的
兽医病理学家,在自然和实验诱导的小鼠病理学方面具有丰富的专业知识
我一直担任核心副主任,监督这项服务,这已被广泛使用
在过去的融资周期中。添加了抗体中央银行,以提供集中的
在之前的资助期间,CURE生产了大量抗体
以及许多研究人员用作特定细胞类型标记的其他抗体,
细胞内信号分子。一个集中的银行的可用性,
CURE感兴趣的经验证抗体:DDRCC研究人员是一个强大的资源,
CURE的有效访问:DDRCC研究人员可以通过
形态学和细胞成像核心。Gordon Ohning博士将作为副主任加入核心,
负责维护中央抗体库。
我们的影像服务能力已大幅提升,包括:
增加了高度复杂的设备,2)采用了新的成像技术,
将进一步提高我们在细胞和亚细胞水平上观察分子的能力,
在细胞激活后的第二信使系统中。我们的成像技术的一个主要丰富
设施已经增加了一个国家的最先进的共聚焦显微镜,蔡司LSM 510 Meta
配备先进的软件(例如解卷积、图像分析、3D渲染),
活细胞和固定细胞成像。该系统是在机构资金的帮助下获得的,
大卫格芬加州大学洛杉矶分校医学院就在之前的竞争性更新,从那时起,它
已被越来越多的CURE:DDRCC研究者大量使用。在过去
在一个受资助的周期中,我们还通过收购蔡司公司的一台
Pascal共聚焦显微镜配备短波长(405 nm)和可见波长激光,
激发全细胞膜片钳记录装置可用于进行单细胞膜片钳记录。
电生理学与共聚焦活细胞成像同时进行。这台显微镜,
在医学院院长办公室机构资金的帮助下获得,位于
加州大学洛杉矶分校在同一建筑物的蔡司510 Meta共焦,并已广泛用于服务
复员方案协调委员会调查员。我们的服务也得到了升级,增加了新的成像
活细胞中的技术,包括量子点(Q-dots),光活化蛋白质和
第二信使的生物传感器标记有荧光标签。这些重大改进将
进一步提高我们在细胞和亚细胞水平上观察大分子的能力,
细胞激活后第二信使系统的变化。奥斯瓦尔多·雷伊博士将加入
作为核心联合主任的人员,负责监督新的成像方法,
许多DDRCC调查人员的新需求。
最后,CURE:DDRCC可用的共享资源将得到更多的使用
调查人员通过核心主任和加州大学洛杉矶分校现有核心的安排进行调查,这些核心是
由病理学和实验室医学系,脑研究所和
纳米技术研究所这些互动将继续是形态学的主要努力,
细胞成像核心,以提高核心的技术能力,并确保最佳利用
UCLA社区内的共享资源,包括CURE:DDRCC社区。
总的来说,增加的服务在上文中简要概述,并在正文的后面进行了更详细的解释。
反映了DDRCC研究兴趣和重点的演变,以及
形态学和成像技术。这些新增内容将提供最先进的方法,
许多CURE:DDRCC研究人员有兴趣阐明基本的正常情况,
或控制消化功能的不同类型细胞的异常机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CATIA STERNINI其他文献
CATIA STERNINI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CATIA STERNINI', 18)}}的其他基金
Extragustatory Functions of Bitter Taste Receptors
苦味感受器的味觉外功能
- 批准号:
8885530 - 财政年份:2015
- 资助金额:
$ 12.17万 - 项目类别:
Mu opioid receptor function in the enteric nervous system
Mu阿片受体在肠神经系统中的功能
- 批准号:
8011605 - 财政年份:2010
- 资助金额:
$ 12.17万 - 项目类别:
ROLE OF GALANIN RECEPTORS IN GASTROINTESTINAL MOTILITY
甘丙肽受体在胃肠动力中的作用
- 批准号:
7226052 - 财政年份:2000
- 资助金额:
$ 12.17万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 12.17万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 12.17万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 12.17万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 12.17万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 12.17万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 12.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 12.17万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 12.17万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 12.17万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 12.17万 - 项目类别: